An exploratory, placebo-controlled, dose–response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity
To explore the dose response to onabotulinumtoxinA 50, 100, and 200 U in patients with spinal cord injury (SCI) with urinary incontinence (UI) due to neurogenic detrusor overactivity (NDO).
Patients (N = 73) with SCI (level T1 or lower) with NDO and UI (≥14 UI episodes/week) received 30 intradetrusor injections of onabotulinumtoxinA (50 U [n = 19], 100 U [n = 21], or 200 U [n = 17]) or placebo (n = 16) via cystoscopy, avoiding the trigone. Changes from baseline in UI episodes/week, volume voided/micturition, maximum cystometric capacity, and maximum detrusor pressure (MDP) during first involuntary detrusor contraction (IDC) were evaluated. Adverse events (AEs) were assessed.
A significant linear dose response for UI episodes/week was identified at weeks 18, 30, 36, 42, and 54 (P < 0.05) with a similar trend (P = 0.092) at week 6 (primary time point). A significant linear dose response was observed in volume/void at all post-treatment time points up to week 54 (P < 0.05) and in MDP during first IDC at week 6 (P = 0.034). The proportion of patients who achieved continence at week 6 was highest in the 200 U group. Duration of effect was longest with the 200 U dose, compared with other treatment groups. The AEs were comparable across groups; urinary tract infection was the most common AE across all treatment groups.
In this exploratory dose–response study of SCI patients with UI due to NDO, onabotulinumtoxinA 200 U was the most effective dose. The AE profile was comparable across all groups.
- Schurch, B, Stohrer, M, Kramer, G, Schmid, DM, Gaul, G, Hauri, D (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164: pp. 692-697
- Mangera, A, Andersson, KE, Apostolidis, A, Chapple, C, Dasgupta, P, Giannantoni, A, Gravas, S, Madersbacher, S (2011) Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol 60: pp. 784-795 CrossRef
- Cruz, F, Herschorn, S, Aliotta, P, Brin, M, Thompson, C, Lam, W, Daniell, G, Heesakkers, J, Haag-Molkenteller, C (2011) Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 60: pp. 742-750 CrossRef
- Ginsberg, D, Gousse, A, Keppenne, V, Sievert, KD, Thompson, C, Lam, W, Brin, M, Jenkins, B, Haag-Molkenteller, C (2012) Phase 3 efficacy and tolerability study of onabotulinumtoxinA in patients with urinary incontinence resulting from neurogenic detrusor overactivity. J Urol 187: pp. 2131-2139 CrossRef
- Karsenty, G, Denys, P, Amarenco, G, Seze, M, Game, X, Haab, F, Kerdraon, J, Perrouin-Verbe, B, Ruffion, A, Saussine, C, Soler, JM, Schurch, B, Chartier-Kastler, E (2008) Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 53: pp. 275-287 CrossRef
- Weld, KJ, Dmochowski, RR (2000) Association of level of injury and bladder behavior in patients with post-traumatic spinal cord injury. Urology 55: pp. 490-494 CrossRef
- Stoehrer, M, Wolff, A, Kramer, G, Steiner, R, Lmochner-Ernst, D, Leuth, D, Steude, U, Ruebben, H (2009) Treatment of neurogenic detrusor overactivity with botulinum toxin A: the first seven years. Urol Int 83: pp. 379-385 CrossRef
- Giannantoni, A, Mearini, E, Zingaro, M, Porena, M (2009) Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol 55: pp. 705-711 CrossRef
- Manack, A, Motsko, SP, Haag-Molkenteller, C, Dmochowski, RR, Goehring, EL, Nguyen-Khoa, BA, Jones, JK (2011) Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. Neurourol Urodyn 30: pp. 395-401 CrossRef
- Schurch, B, Seze, M, Denys, P, Chartier-Kastler, E, Haab, F, Everaert, K, Plante, P, Perrouin-Verbe, B, Kumar, C, Fraczek, S, Brin, MF (2005) Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174: pp. 196-200 CrossRef
- An exploratory, placebo-controlled, dose–response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity
World Journal of Urology
Volume 31, Issue 6 , pp 1469-1474
- Cover Date
- Print ISSN
- Online ISSN
- Springer Berlin Heidelberg
- Additional Links
- Neurogenic detrusor overactivity
- Urinary incontinence
- Botulinum toxin
- Industry Sectors
- Author Affiliations
- 1. 2nd Department of Urology, Papageorgiou General Hospital, Aristotle University of Thessaloniki, 56403, Thessaloníki, Greece
- 2. Allergan, Ltd., Marlow, Buckinghamshire, UK
- 3. Allergan Inc., Irvine, CA, USA
- 4. Ain Shams University, Cairo, Egypt